{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Moscovitch-Lopatin M"],"funding":["NHGRI NIH HHS","NINDS NIH HHS"],"pagination":["1134-40"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3795598"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["81(13)"],"pubmed_abstract":["<h4>Objective</h4>We measured the levels of mutant huntingtin (mtHtt) and total huntingtin (tHtt) in blood leukocytes from Prospective Huntington At-Risk Observational Study (PHAROS) subjects at 50% risk of carrying the Huntington disease mutation using a homogeneous time-resolved fluorescence (HTRF) assay to assess its potential as a biomarker.<h4>Methods</h4>Peripheral blood mononuclear cells from consenting PHAROS subjects were analyzed by HTRF using antibodies that simultaneously measured mtHtt and tHtt. mtHtt levels were normalized to tHtt, double-stranded DNA, or protein and analyzed according to cytosine-adenine-guanine repeat length (CAGn), demographics, predicted time to clinical onset or known time since clinical onset, and available clinical measures.<h4>Results</h4>From 363 ass"],"journal":["Neurology"],"pubmed_title":["HTRF analysis of soluble huntingtin in PHAROS PBMCs."],"pmcid":["PMC3795598"],"funding_grant_id":["UO1NS071789","P01NS058793","HG02449-01","U01 NS071789"],"pubmed_authors":["Goodman RE","Matson S","Moscovitch-Lopatin M","Shoulson I","Matson W","Rosas HD","Young AB","Hersch SM","Huntington Study Group PHAROS Investigators","Eberly S","Ritch JJ","Oakes D"],"additional_accession":[]},"is_claimable":false,"name":"HTRF analysis of soluble huntingtin in PHAROS PBMCs.","description":"<h4>Objective</h4>We measured the levels of mutant huntingtin (mtHtt) and total huntingtin (tHtt) in blood leukocytes from Prospective Huntington At-Risk Observational Study (PHAROS) subjects at 50% risk of carrying the Huntington disease mutation using a homogeneous time-resolved fluorescence (HTRF) assay to assess its potential as a biomarker.<h4>Methods</h4>Peripheral blood mononuclear cells from consenting PHAROS subjects were analyzed by HTRF using antibodies that simultaneously measured mtHtt and tHtt. mtHtt levels were normalized to tHtt, double-stranded DNA, or protein and analyzed according to cytosine-adenine-guanine repeat length (CAGn), demographics, predicted time to clinical onset or known time since clinical onset, and available clinical measures.<h4>Results</h4>From 363 ass","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Sep","modification":"2026-05-02T09:38:30.503Z","creation":"2019-03-27T01:17:08Z"},"accession":"S-EPMC3795598","cross_references":{"pubmed":["23966247"],"doi":["10.1212/WNL.0b013e3182a55ede","10.1212/wnl.0b013e3182a55ede"]}}